+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Exosomes - Pipeline Insight, 2021

  • ID: 5337990
  • Clinical Trials
  • July 2021
  • Region: Global
  • 200 pages
  • DelveInsight

FEATURED COMPANIES

  • Aegle Therapeutics
  • ArunA Biomedical
  • Avalon GloboCare
  • Azymus Therapeutics
  • Capricor Therapeutics
  • Direct Biologics
This Exosomes - Pipeline Insight, 2021 provides comprehensive insights about 55+ companies and 70+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Exosomes Understanding


Exosomes: Overview


Exosomes are a type of extracellular vesicle, a family of nanometer-scale, biomolecule-filled, lipid-wrapped packages that contain constituents (protein, DNA, and RNA) of the cells that secrete them. Exosomes can be a highly heterogeneous population and have distinct abilities to induce a complex biological response. Exosomes are isolated from a wide spectrum of biological fluids, including blood, urine, saliva and breast milk. Exosomes are generated in a process that involves double invagination of the plasma membrane and the formation of intracellular multivesicular bodies containing intraluminal vesicles. Exosomes are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Exosomes have therapeutic potential to control many diseases, along with aid in disease diagnosis. Extensive studies are going on for the role of exosomes in the diagnosis and treatment of various pathologies.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D. The therapies under development are focused on novel approaches for Exosomes.

Exosomes Emerging Drugs Chapters


This segment of the Exosomes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Exosomes Emerging Drugs


ExoFlo: Direct Biologics

ExoFlo is an investigational new drug that has not been approved or licensed by the FDA. It is an extracellular vesicle product isolated from human bone marrow mesenchymal stem or stromal cells (MSCs). The drug is in Phase II clinical development for the treatment of Covid19, ARDS, and viral pneumonia. In October 2020, The US Food and Drug Administration (FDA) granted expanded access for Direct Biologics' ExoFlo, allowing it to be used to treat patients with COVID-19-associated acute respiratory distress syndrome. It is currently in phase II stage of development and is being developed by Direct Biologics.

Progenza: Regeneus

Progenza is being developed by Regeneus, and is currently in the Phase II stage of development for Osteoarthritis and preclinical for Neuropathic Pain. Progenza is a cellular therapy targeting pain and inflammation which uses Secretome to improve not only the resident tissue but the Mesenchymal Signalling Cells (MSCs) themselves.

Exosomes: Therapeutic Assessment


This segment of the report provides insights about the different Exosomes drugs segregated based on following parameters that define the scope of the report, such as:


Major Players working on Exosomes


There are approx. 55+ key companies which are developing the Exosomes. The companies which have their Exosomes drug candidates in the most advanced stage, i.e. Phase II include, Direct Biologics.

Phases


This report covers around 70+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Exosomes: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Exosomes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exosomes drugs.

Exosomes Report Insights

  • Exosomes Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Exosomes Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Scenario and Emerging Therapies:

  • How many companies are developing Exosomes drugs?
  • How many Exosomes drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Exosomes?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Exosomes therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Exosomes and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Direct Biologics
  • Capricor
  • Regeneus
  • AVEM HealthCare
  • Aegle Therapeutics
  • Organicell Regenerative Medicine
  • Codiak Biosciences
  • United Therapeutics
  • ArunA Biomedical
  • Evox Therapeutics
  • ArunA Biomedical
  • MolecuVax
  • Versatope Therapeutics
  • Lamellar Biomedical
  • Azymus Therapeutics
  • Alxerion Biotech
  • Avalon GloboCare
  • Capricor Therapeutics

Key Products

  • ExoFlo
  • CAP-1002
  • Progenza
  • Mesenchymal stem cells (MSCs) exosomes
  • AGLE 102
  • Zofin
  • exoIL-12
  • exoSTING
  • UNEX 42
  • AB 126
  • EVX-102
  • AB 127
  • EVX-101
  • AB 128
  • MVAX 001
  • VT 105
  • IPF-Lamellasome
  • Muco-ease
  • AZ-001
  • ALX-029
  • ALX-102
  • AVA-201
  • CAP 2003
  • AVA 203

This report will be delivered within 2 business days.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aegle Therapeutics
  • ArunA Biomedical
  • Avalon GloboCare
  • Azymus Therapeutics
  • Capricor Therapeutics
  • Direct Biologics
Introduction

Executive Summary

Exosomes: Overview
  • Structure
  • Mechanism of Action
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
Late Stage Products (Phase III)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
ExoFlo: Direct Biologics
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
UNEX 42: United Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
EVX-102: Evox Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Exosomes Key Companies

Exosomes Key Products

Exosomes- Unmet Needs

Exosomes- Market Drivers and Barriers

Exosomes- Future Perspectives and Conclusion

Exosomes Analyst Views

Exosomes Key Companies

Appendix

List of Tables
Table 1 Total Products for Exosomes
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Exosomes
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Direct Biologics
  • Capricor
  • Regeneus
  • AVEM HealthCare
  • Aegle Therapeutics
  • Organicell Regenerative Medicine
  • Codiak Biosciences
  • United Therapeutics
  • ArunA Biomedical
  • Evox Therapeutics
  • ArunA Biomedical
  • MolecuVax
  • Versatope Therapeutics
  • Lamellar Biomedical
  • Azymus Therapeutics
  • Alxerion Biotech
  • Avalon GloboCare
  • Capricor Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll